RESUMO
Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review provides a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action. From the perspective of indications, this article presents an overview of the applications of nanomedicines involving the prevention, diagnosis and treatment of various diseases, which include cancer, infections, blood disorders, cardiovascular diseases, immuno-associated diseases and nervous system diseases, etc. Moreover, the review provides some considerations and perspectives in the research and development of nanomedicines to facilitate their translations in clinic.
RESUMO
The purpose of the study was to develop a simple, sensitive and rapid RP-HPLC method for the determination of Midazolam in marketed products. Chromatographic determination was performed in a reverse phase C18 column (250 mm × 3.3 mm I.D. , 5μm particle size) using a mixture of acetonitrile: methanol: 0.065 M ammonium acetate buffer (50:20:30, v/v/v), final pH adjust to 5.5 ± 0.02 with ortho phosphoric acid as mobile phase and delivered at a flow rate of 1 ml/min. The UV detection was set at 220 nm. The calibration range was from 2.0 to 30.0 μg/ml. The method was validated in term of linearity (r2>0.98, RSD= 1.958%), precision (RSD=3.757 %) and accuracy. The limit of quantification was 2 μg/ml and the limit of detection was 0.1 μg/ml. The potency of midazolam in marketed products was determined by this method with acceptable precision and reproducibility.